Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1949 1
1950 6
1951 4
1952 1
1953 1
1954 2
1955 2
1956 2
1957 2
1958 2
1959 3
1961 3
1962 3
1963 5
1964 2
1965 1
1966 2
1967 3
1968 5
1971 1
1975 1
1980 1
1988 1
1989 1
1990 1
1991 1
1994 1
1995 1
1996 1
1997 2
1998 5
1999 5
2000 3
2002 1
2003 2
2005 1
2006 4
2007 3
2008 4
2009 5
2010 4
2011 2
2012 8
2013 6
2014 3
2015 7
2016 7
2017 6
2018 5
2019 4
2020 15
2021 8
2022 8
2023 5
2024 8
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.
Blackstone J, Williams T, Nicholas JM, Bordea E, De Angelis F, Bianchi A, Calvi A, Doshi A, John N, Apap Mangion S, Wade C, Merry R, Barton G, Lyle D, Jarman E, Mahad D, Shehu A, Arun T, McDonnell G, Geraldes R, Craner M, Hillier C, Ganesalingam J, Fisniku L, Hobart J, Spilker C, Robertson N, Kalra S, Pluchino S, Harikrishnan S, Mattoscio M, Harrower T, Young C, Lee M, Chhetri S, Ahmed F, Rog D, Silber E, Gallagher P, Duddy M, Straukiene A, Nicholas R, Rice C, Nixon SJ, Beveridge J, Hawton A, Tebbs S, Braisher M, Giovannoni G, Ciccarelli O, Greenwood J, Thompson AJ, Hunter R, Pavitt S, Pearson O, Evangelou N, Sharrack B, Galea I, Chandran S, Ford HL, Frost C, Chataway J. Blackstone J, et al. Among authors: silber e. BMJ Open. 2024 Sep 16;14(9):e086414. doi: 10.1136/bmjopen-2024-086414. BMJ Open. 2024. PMID: 39284697 Free PMC article.
Osmotic demyelination syndrome.
Abbott R, Silber E, Felber J, Ekpo E. Abbott R, et al. Among authors: silber e. BMJ. 2005 Oct 8;331(7520):829-30. doi: 10.1136/bmj.331.7520.829. BMJ. 2005. PMID: 16210283 Free PMC article. No abstract available.
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.
Chataway J, Williams T, Blackstone J, John N, Braisher M, De Angelis F, Bianchi A, Calvi A, Doshi A, Apap Mangion S, Wade C, Bordea E, Merry R, Barton G, Lyle D, Jarman E, Mahad D, Shehu A, Arun T, McDonnell G, Geraldes R, Craner M, Hillier C, Ganesalingam J, Fisniku L, Hobart J, Spilker C, Robertson NP, Kalra S, Pluchino S, Harikrishnan S, Mattoscio M, Harrower T, Young C, Lee M, Chhetri SK, Ahmed F, Rog D, Silber E, Gallagher P, Duddy M, Straukiene A, Nicholas R, Rice C, Tebbs S, Hawton A, Hunter R, Giovannoni G, Ciccarelli O, Beveridge J, Nixon S, Thompson AJ, Greenwood J, Pearson OR, Evangelou N, Sharrack B, Galea I, Gray E, Pavitt S, Chandran S, Ford HL, Frost C, Nicholas JM; MS-STAT2 Investigators. Chataway J, et al. Among authors: silber e. Lancet. 2025 Oct 11;406(10512):1611-1624. doi: 10.1016/S0140-6736(25)01039-6. Epub 2025 Oct 1. Lancet. 2025. PMID: 41045938 Free article. Clinical Trial.
Osteoporosis in multiple sclerosis.
Hearn AP, Silber E. Hearn AP, et al. Among authors: silber e. Mult Scler. 2010 Sep;16(9):1031-43. doi: 10.1177/1352458510368985. Epub 2010 Jun 15. Mult Scler. 2010. PMID: 20551086 Review.
Diabetes and neurology: hemichorea-hemiballism in hyperglycaemia.
Galloway KY, Younus O, Quattrocchi G, Raheem B, Dervenoulas G, Silber E. Galloway KY, et al. Among authors: silber e. Clin Med (Lond). 2020 Mar;20(Suppl 2):s21-s22. doi: 10.7861/clinmed.20-2-s21. Clin Med (Lond). 2020. PMID: 32409348 Free PMC article. No abstract available.
Real-world incidence of fingolimod-associated macular oedema.
Goh LY, Kirthi V, Silber E, Harvey JP, Jackson TL. Goh LY, et al. Among authors: silber e. Mult Scler Relat Disord. 2020 Jul;42:102125. doi: 10.1016/j.msard.2020.102125. Epub 2020 Apr 28. Mult Scler Relat Disord. 2020. PMID: 32403070
190 results